A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Plantar fasciitis
- Focus Therapeutic Use
- Sponsors Revance Therapeutics
- 03 Nov 2017 According to a Revance Therapeutics media release, company will report topline 8-week safety and efficacy results at year-end.
- 18 Oct 2017 According to a Revance Therapeutics media release, company anticipates to report top line data before year end.
- 18 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Revance Therapeutics media release.